Surgical Resection for Pancreatic Cancer

2010 ◽  
pp. 971-996 ◽  
Author(s):  
Nuh N. Rahbari ◽  
Nathan Mollberg ◽  
Moritz Koch ◽  
John P. Neoptolemos ◽  
Jürgen Weitz ◽  
...  
PLoS Medicine ◽  
2016 ◽  
Vol 13 (8) ◽  
pp. e1002108 ◽  
Author(s):  
Livia S. Eberlin ◽  
Katherine Margulis ◽  
Ivette Planell-Mendez ◽  
Richard N. Zare ◽  
Robert Tibshirani ◽  
...  

Oncotarget ◽  
2016 ◽  
Vol 7 (17) ◽  
pp. 24880-24887 ◽  
Author(s):  
Xiao-Dong Wang ◽  
Jian-Jun Qian ◽  
Dou-Sheng Bai ◽  
Zhen-Nan Li ◽  
Guo-Qing Jiang ◽  
...  

2021 ◽  
Vol 7 ◽  
Author(s):  
Muhammad Nadeem Yousaf ◽  
Hamid Ehsan ◽  
Ahmad Muneeb ◽  
Ahsan Wahab ◽  
Muhammad K. Sana ◽  
...  

Pancreatic cancer is one of the most aggressive malignancies of the digestive tract and carries a poor prognosis. The majority of patients have advanced disease at the time of diagnosis. Surgical resection offers the only curative treatment, but only a small proportion of patients can undergo surgical resection. Radiofrequency ablation (RFA) is a well-known modality in the management of solid organ tumors, however, its utility in the management of pancreatic cancer is under investigation. Since the past decade, there is increasing use of RFA as it provides a feasible palliation treatment in the management of unresectable pancreatic cancer. RFA causes tumor cytoreduction through multiple mechanisms such as coagulative necrosis, protein denaturation, and activation of anticancer immunity. The safety profile of RFA is controversial because of the high risk for complications, however, small prospective and retrospective studies have shown promising results in its applicability for palliative management of unresectable pancreatic malignancies. In this review, we discuss different approaches of RFA, their indications, technical accessibility, safety, and major complications in the management of unresectable pancreatic cancer.


2016 ◽  
Vol 23 (S5) ◽  
pp. 730-736 ◽  
Author(s):  
Franz Mierke ◽  
Sebastian Hempel ◽  
Marius Distler ◽  
Daniela E. Aust ◽  
Hans-Detlev Saeger ◽  
...  

2021 ◽  
pp. 1-7
Author(s):  
Soichiro Ako ◽  
Hironari Kato ◽  
Kazuhiro Nouso ◽  
Hideaki Kinugasa ◽  
Hiroyuki Terasawa ◽  
...  

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Hyeong Min Park ◽  
Sang-Jae Park ◽  
Sung-Sik Han ◽  
Seoung Hoon Kim

Abstract Background We designed a retrospective study to compare prognostic outcomes based on whether or not surgical resection was performed in elderly patients aged(≥75 years) with resectable pancreatic cancer. Methods We retrospectively analyzed 49 patients with resectable pancreatic cancer (surgery group, resection was performed for 38 cases; no surgery group, resection was not performed for 11 cases) diagnosed from January 2003 to December 2014 at the National Cancer Center, Korea. Results There was no significant difference in demographics between the two groups. The surgery group showed significantly better overall survival after diagnosis than the no surgery group (2-year survival rate, 40.7% vs. 0%; log-rank test, p = 0.015). Multivariate analysis revealed that not having undergone surgical resection [hazard ratio (HR) 2.412, P = 0.022] and a high Charlson comorbidity index (HR 5.252, P = 0.014) were independent prognostic factors for poor overall survival in elderly patients with early stage pancreatic cancer. Conclusions In the present study, surgical resection resulted in better prognosis than non-surgical resection for elderly patients with resectable pancreatic cancer. Except for patients with a high Charlson comorbidity index, an aggressive surgical approach seems to be beneficial for elderly patients with resectable pancreatic cancer.


HPB ◽  
2019 ◽  
Vol 21 ◽  
pp. S90-S91
Author(s):  
A.M. Altman ◽  
K. Wirth ◽  
S. Marmor ◽  
K. Chang ◽  
E. Lou ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document